Answers are grounded in this paper and cite their sources.
T cells, nor ZIKV neutralizing antibodies are required to confer protection against YFV. The chimeric YF-ZIKprM/E vaccine may thus be considered as a dual vaccine candidate efficiently protecting mice against both the ZIKV and the YFV, and this following a single dose immunization. Our finding may be particularly important in the rational design of vaccination strategies against flaviviruses, in particular in areas where YFV and ZIKV co-circulate.
No takes yet. Share an insight, caveat, or question.
Kum et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: